Tag:
Gilead Sciences
Latest Headlines
Latest Headlines
Who's who in Big Pharma offers appetizing look at ASCO data
With the big American Society of Clinical Oncology meeting coming up in two weeks, anticipation about the coming onslaught of data is mounting. Last night, ASCO released some key abstracts for studies to be presented at the meeting, offering an aperitif to oncology-drug followers. Here is a sampling of news, some from our sister publication FierceBiotech.
Which Big Biotechs are hitting the gas pedal on R&D spending?
The R&D numbers for the top 10 biotechs may only amount to a fraction of what you'll find in Big Pharma. But unlike the giants, which are trying to keep a lid on multibillion-dollar budgets, you'll find a much faster crowd when you turn your gaze to the biotechs.
Gilead profits surge 63%, but not where Wall Street expected
Gilead Sciences was in a position to say, "I told you so," when its first quarter earnings fell a little short of Wall Street expectations Thursday. Profits were still up 63% even as sales of older HIV drugs came in shy of forecasts.
Manufacturing issues trip up approval for Gilead, Impax
Once drugs are approved, manufacturing is supposed to kick in and get the product out the door so drugmakers can start making some money. But recently, questions about manufacturing have not only been a stumbling block for some companies to getting approvals, they have broken up a relationship.
FDA rejects two of the four drugs in Gilead's blockbuster HIV drug Stribild
The refusals for elvitegravir and cobicistat on a standalone basis were triggered after inspectors were left shaking their heads following a checkup on Gilead's "documentation and validation of certain quality testing procedures and methods."
Shunned Gilead/Bristol-Myers hep C combo may be too good for docs to ignore
Rival drug combination works to perfection for toughest hep C patient group, and some patients and doctors appear willing to consider taking matters into their own hands.
Humira carries AbbVie in its first quarter as standalone company
AbbVie's rheumatoid arthritis drug Humira did exactly what the new company needed it to do in the first quarter. It returned significantly higher sales and allowed Abbvie to report better than expected earnings in its first earnings report as a stand-alone company.
Gilead keeps lead in hep C race after rivals post key trial results
After delivering data from multiple rounds of trials on all-oral combos against hepatitis C, pharma runners appear to be making progress with new therapies that could shorten treatment durations and wipe out the liver-damaging virus without infusions of interferon and the flulike side effects that go with them.
Which drugs are the biggest duds in blockbuster-land?
EvaluatePharma researchers totted up sales for the last 5 years' worth of analysts' blockbuster picks--and found plenty of bad bets.
Gilead quickly asks FDA for blockbuster hep C approval
Gilead Sciences moved up again in the hepatitis C race. With a bunch of companies hurrying along all-oral programs, Gilead has taken an application to the FDA for approval of its hep C pill sofosbuvir (GS-7977), positioning itself to become the first pharma group with a completely oral regimen on the U.S. market.
